Paris, June 3 -- French pharmaceutical giant Sanofi is buying American biopharmaceutical company Blueprint Medicines Corporation for $9.1 billion, Sanofi said in a statement.
"Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis (SM), a rare immunological disease, and other KIT-driven diseases, have entered into an agreement under which Sanofi will acquire Blueprint," the statement said.
Pursuant to the terms of the merger agreement, Sanofi will submit a tender offer to acquire in cash all of the outstanding shares of Blueprint at a price of $129 per share, which will amount to an equity value of approximately $9.1 billion, it added.
Sanofi not...